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In earlier experiments, we have produced evidence that activation of XBP-1 occurs even in B cells that do not synthesize massive quantities of sIgM (10) . In this study, we set out to examine whether the presence or absence of XBP-1, through its impact on ER homeostasis, affects glycoprotein folding in B cells. To that end, we generated mice in which XBP-1 is conditionally deleted in B cells by crossing the XBP-1 flox/flox mouse line (XBP-1 WT , where WT represents wild type) (11) to mice in which expression of Cre recombinase is under the control of the B cell-specific CD19 promoter (12) , henceforth referred to as XBP-1 KO (where KO represents knockout) mice. In addition to the XBP-1 KO mice, we used mice unable to synthesize sIgM (XBP-1 KO /S Ϫ/Ϫ ) (13) , and thus expressing only mIgM. Finally, we used transgenic MD4 mice (XBP -1 WT /MD4 and XBP-1 KO /MD4) in which both the H and L chains of IgM specifically recognize hen egg lysozyme (HEL) (14) ; this mouse model allowed us to investigate the Ag reactivity of IgM produced in the absence of XBP-1, a rigorous test of successful glycoprotein synthesis, folding, and assembly.
Lipids are not template encoded and cannot be manipulated by genetic mutation as readily as proteins, but they are important in physiology. Enforced expression of XBP-1s in NIH3T3 fibroblasts established the role of XBP-1 in controlling synthesis of phosphatidylcholine (PC) and phosphatidylethanolamine (15, 16) . Although a liver-specific KO of XBP-1 leads to hypocholesterolemia and hypotriglyceridemia, a lipomics analysis shows that lipid composition in hepatocytes is not affected by XBP-1 deficiency (17) . These results suggested that XBP-1 can regulate expression of a tissue-specific lipid profile in individual organs. The changes in lipid composition have not been systematically examined in the context of B cells with a deficiency in XBP-1. A change in lipid synthesis can alter lipid environments (such as lipid rafts), making B cells respond differently to stimulation with Ag.
In this study, we show that XBP-1-deficient B cells are fully capable of correctly folding both sIgM and mIgM. Our investigation of the biogenesis of a number of essential membrane proteins in XBP-1-deficient B cells revealed no defects in their synthesis, folding, assembly, or intracellular transport. XBP-1-deficient B cells also secrete free -chains at rates comparable to those seen in XBP-1-proficient cells. Examination of the lipid contents in total membranes of XBP-1-deficient B cells shows decreased levels of a select group of lipids. XBP-1-deficient B cells expand their ER in response to LPS stimulation, but do so to a lesser extent than WT B cells. A subtly altered pattern of terminal N-linked glycosylation was observed for IgM as well as class I MHC products. We conclude that the operation of the secretory pathway shows no obvious abnormalities in XBP-1-deficient B cells, and that XBP-1 is required in differentiating B cells for processes other than the up-regulation of ER-folding capacity.
Materials and Methods

Mice
XBP-1
flox/flox mice have been described (11) . To obtain B cell-specific deletion, XBP-1 flox/flox mice were crossed with CD19-Cre mice (12) obtained from Y. Shi (Harvard Medical School, Boston, MA). Mice with a B cellspecific XBP-1 deletion were additionally crossed to secreted knockout (S Ϫ/Ϫ ) mice (13) or to MD4 mice (14) , which harbor a transgene for HEL-specific IgM.
Abs and reagents
Polyclonal Abs against Ig␣, Ig␤, and protein disulfide isomerase (PDI) were generated in rabbits. Class I MHC was detected using p8 antiserum directed against the cytoplasmic tail, and class II MHC was detected using JV1 antiserum directed against the class II ␣-chain. Reagents purchased from commercial sources include Abs to actin (Sigma-Aldrich), p97 (Fitzgerald), XBP-1 (Santa Cruz Biotechnology), (Southern Biotechnology Associates), and (Southern Biotechnology Associates). FACS Abs were purchased from BD Pharmingen, and the following clones were used: CD40 (3/23), CD80 (16-10A1), and CD1d (1B1). Ligands to TLRs were procured from commercial sources, as follows: Pam 3 CSK 4 from Alexis Biochemicals; poly(I:C) and LPS (Escherichia coli O26:B6) from Sigma-Aldrich; imiquimod from InvivoGen; and CpG DNA from TIB-MOLBIOL.
Cell culture
B lymphocytes were purified from mouse spleens by negative selection using anti-CD43 magnetic beads (Miltenyi Biotec). B cells were cultured in the RPMI 1640 medium (Life Technologies) supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin G sodium, 100 g/ml streptomycin sulfate, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, and 0.1 mM 2-ME. For differentiation of B cells into plasmablasts, LPS (20 g/ml) was added to the culture medium. The NKT cell hybridoma 24.7 (18) was a gift of S. Behar (Brigham and Women's Hospital, Boston, MA). IL-2 and IL-6 concentrations were measured by ELISA (BD Pharmingen).
Protein isolation and immunoblotting
Cells were lysed in Nonidet P-40 lysis buffer (50 mM Tris (pH 7.4), 0.5% Nonidet P-40, 5 mM MgCl 2 , and 150 mM NaCl) or radioimmunoprecipitation assay buffer (10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, and 1 mM EDTA) supplemented with protease inhibitor mixture (Roche). The protein concentrations of the supernatants were determined by bicinchoninic acid assay (Pierce). Samples were boiled in SDS-PAGE sample buffer (62.5 mM TrisHCl (pH 6.8), 2% SDS, 10% glycerol, and 0.1% bromphenol blue) with 2-ME (or N-ethylmaleimide (NEM) where indicated) and separated by SDS-PAGE. Proteins were transferred to nitrocellulose or polyvinylidene difluoride membranes, blocked in 5% (w/v) milk, and immunoblotted with the indicated Abs and appropriate HRP-conjugated secondary Abs. Following three washes in PBS-Tween 20 (0.1%), the blots were developed using Western Lighting Chemiluminescence Reagent (PerkinElmer).
Pulse-chase labeling
Pulse-chase experiments were performed, as described (19) . Briefly, plasmablasts were starved in methionine-and cysteine-free medium, then pulse labeled with [ 35 S]methionine/cysteine (PerkinElmer). After labeling, cells were incubated in chase medium containing unlabeled methionine (2.5 mM) and cysteine (0.5 mM). At the end of each chase interval, cells were lysed in radioimmunoprecipitation assay buffer containing protease inhibitors. Lysates were then analyzed by immunoprecipitation, SDS-PAGE, and fluorography. Band intensity was determined using a phosphor imager (Fujifilm BAS 2500), and quantitation was done using the MultiGauge software (Fujifilm).
FACS analysis
Live plasmablasts were stained with the indicated Abs and analyzed by a FACSCalibur flow cytometer (BD Biosciences). Data were analyzed using CellQuest (BD Biosciences).
Triton X-114 phase separation
Triton X-114 phase separation was performed, as described (20) . Briefly, cells were lysed in Triton X-114 lysis buffer (10 mM Tris-HCl (pH 7.4), 150 mM NaCl, and 1% Triton X-114) containing protease inhibitors. Lysates were placed onto a sucrose cushion (6% sucrose, 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, and 0.06% Triton X-114), and incubated at 30°C until the lysates turned cloudy. The detergent phase was recovered by centrifugation for 5 min at 300 ϫ g. The aqueous supernatant was removed and re-extracted with 0.5% Triton X-114, and overlaid onto the original sucrose cushion. After a subsequent round of separation, both the detergent (sediment) and the soluble (supernatant) fractions were brought to the same buffer and detergent concentrations for further analysis.
Biotinylated HEL affinity purification of HEL-specific Igs
Cells were metabolically labeled and subjected to Triton X-114 phase separation, as described above. Samples were incubated with either anti-, biotinylated HEL, or unconjugated biotin. Proteins were then recovered with either protein G-agarose beads or anti-biotin beads (Sigma-Aldrich), washed, eluted with SDS-PAGE sample buffer, and analyzed by SDS-PAGE. For serial depletions using biotinylated HEL, supernatants from the initial purification were subjected to five sequential rounds of retrieval by biotinylated HEL, and a final round of immunoprecipitation using the anti-Ab.
Enzymatic deglycosylation
Total lysates or immunoprecipitates from lysates were denatured in glycoprotein denaturing buffer (0.5% SDS, 1% 2-ME) at 95°C for 5 min, followed by addition of sodium citrate (pH 5.5) to a final concentration of 50 mM, and incubated with endoglycosidase H (Endo H) (New England Biolabs) at 37°C for 2 h. Alternatively, sodium phosphate (pH 7.5) and Nonidet P-40 were added to the denatured cell lysates to a final concentration of 50 mM and 1%, respectively, and the mixture was incubated with peptide: N-glycosidase F (PNGase F) (New England Biolabs) at 37°C for 2 h.
Liquid chromatography-mass spectrometry analysis of lipids
Lipid extract was prepared using a modified version of Bligh and Dyer method (21) , with two sequential extraction steps to maximize yield. A total of 0.9 ml of a chloroform:methanol (1:2) mix was added to 10 million cells (in 0.1 ml of PBS), and the mixture was vortexed vigorously for 3 ϫ 1 min with a 5-min interval in between. Next, 0.3 ml of chloroform and 0.3 ml of 1 M KCl were added to the tube, and the mixture was again vortexed. The mixture was then centrifuged for 2 min at 9000 rpm to separate the phases. The lower organic layer was transferred to a clean microfuge tube. Residual aqueous phase and cell remnants were re-extracted with 0.5 ml of chloroform, as described above, and the organic phase was combined with extract 1. The combined extract was dried in a Speedvac. Before analysis, lipids were dissolved in chloroform/methanol (1:1, v/v).
An Agilent HPLC system coupled with an Applied Biosystems Triple Quadrupole/Ion Trap mass spectrometer (4000Qtrap) was used for quantification of individual polar lipids. Based on product ion and precursor ion analyses of head groups, two comprehensive sets of multiple reaction monitoring transitions were set up for quantitative analysis of various lipids, including PC, phosphatidylethanolamine, phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidylglycerol (PG), sphingomyelin (SM), and ceramide (Cer) (22, 23) . The signal intensity obtained for each lipid species was calculated by comparing to corresponding internal standards, including di14:0-PC, di14:0-phosphatidylethanolamine, di14:0-PS, di14:0-PG, di8: 0-PI, Cer d18:1/17:0, and SM18/14:0.
Electron microscopy B cells were fixed for electron microscopy either immediately after isolation, or after 3 days in culture in the presence of LPS. The cells were fixed in 2.5% glutaraldehyde, 3% paraformaldehyde, with 5% sucrose in 0.1 M sodium cacodylate buffer (pH 7.4). Cells were then postfixed in 1% OsO 4 in veronal-acetate buffer. The cells were stained in block overnight with 0.5% uranyl acetate in veronal-acetate buffer (pH 6.0), dehydrated, and embedded in Spurr's resin. Sections were cut on a Reichert Ultracut E microtome with a Diatome diamond knife at a thickness setting of 50 nm, and stained with 2% uranyl acetate, followed by 0.1% lead citrate. Samples were examined using an FEI Tecnai Spirit TEM at 80 KV and imaged with an AMT camera.
Results
XBP-1 activation occurs in the absence of sIgM
We set out to test the connection between XBP-1 and glycoprotein quality control during B cell differentiation. B cells were analyzed over the course of a 4-day in vitro differentiation scheme in which naive splenic B cells were cultured in the presence of LPS, to induce differentiation into Ig-secreting plasmablasts (24) .
We assessed the expression of XBP-1s in B cells from S Ϫ/Ϫ mice over 4 days of in vitro LPS-stimulated differentiation. XBP-1s was induced as early as day 1, and its expression persisted for the remainder of the time in culture (Fig. 1A ) (10) . This expression pattern is similar to what is observed in WT mice (10, 25) .
showed upregulation of PDI following LPS stimulation (Fig. 1A) , indicating that up-regulation of PDI requires both LPS and XBP-1s.
Because S Ϫ/Ϫ B cells do not express sIgM, but are readily induced by LPS to express XBP-1, activation of XBP-1 in these B cells cannot be due to an accumulation of unfolded sIgM. We therefore investigated the expression of membrane (M), , Ig␣, and class I and II MHC molecules in S Ϫ/Ϫ B cells to determine whether there was an aberration in the expression of proteins other than IgM that could result in an accumulation of unfolded proteins and activation of XBP-1. The M was only modestly up-regulated over the 4-day time course of differentiation in both control and XBP-1-deficient B cells (Fig. 1B) . This increase is insignificant when compared with the increase of sIgM upon LPS stimulation in normal B cells; in XBP-1-proficient cells, sIgM levels increase by at least 15-fold (25) . In both XBP-1-deficient and -proficient B cells, expression of -chain increased over the course of LPS stimulation and was increased in XBP-1-deficient B cells (Fig. 1B) . However, free -chains are unlikely to be the trigger for XBP-1 activation, because pulse-chase experiments showed that these -chains are secreted normally (see below). Expression of Ig␣ remained constant over the 4-day course of LPS stimulation, and MHC molecules were slightly up-regulated after LPS stimulation (Fig. 1B) .
The absence of XBP-1 does not alter the efficiency of IgM folding
The defect attributable to the absence of XBP-1 is expected to yield systemic folding defects in glycoproteins due to dysregulation of chaperone synthesis. Such a defect could manifest itself in several ways, as follows: an increase in misfolded proteins, a defect in protein assembly, or a decrease in trafficking from the ER to the targeted locations.
We performed a stringent test for the presence of misfolded IgM, using MD4 transgenic mice that express IgM specific for HEL. Ag binding represents a robust test of correct folding and assembly of IgM, because Ag-Ab interaction requires both correct folding and assembly of the H and L chains. To isolate correctly folded IgM from MD4 B cells, the Ag HEL was conjugated to biotin, which was then used to recover IgM capable of recognizing HEL by adsorption to anti-biotin agarose beads. We performed these experiments following separation of mIgM and sIgM using the Triton X-114 phase separation method (20) . By retrieval of IgM using biotinylated HEL, we found that the majority of IgM recovered from MD4 B cells is indeed specific for HEL, because immobilized biotinylated HEL led to retrieval of IgM only from MD4, but not from WT B cells ( Fig. 2A) . There was no obvious difference in the percentage of HEL-reactive IgM recovered from XBP-1
WT /MD4 and XBP-1 KO /MD4 B cells (Fig. 2, B and C) . After five rounds of sequential retrieval with immobilized biotinylated HEL, we recovered the remaining unfolded IgM by and XBP-1 KO / MD4), the amount of recovered from the first fraction by immunoprecipitation using the anti-Ab was designated as the total . By comparing with the total , the percentage of recovered from the second fraction was designated for each of the five sequential biotinylated HEL recovery steps and for the final recovery with the anti-Ab. The quantitation of S (B) was performed on fractions taken from the Triton X-114 supernatant, and the M quantitation (C) was performed on the Triton X-114 pellet fractions. The results shown are an average of two separate experiments.
immunoprecipitation using an anti-Ab. Had the ability of IgM to fold properly been compromised by the XBP-1 deficiency, we should have detected a surplus of free, unbound -chains in XBP-1-deficient MD4 B cells, but this was not the case. We observed no significant differences in the percentage of misfolded IgM between XBP-1 WT /MD4 and XBP-1 KO /MD4 B cells, suggesting a similar ability to correctly fold both sIgM and mIgM (Fig. 2, B and C) .
Ig␣/Ig␤ heterodimer formation proceeds normally in XBP-1-deficient B cells
Ig␣ must assemble with Ig␤ before the heterodimer can leave the ER. To assess the association of Ig␣ with Ig␤, we radiolabeled both naive and 3-day LPS-stimulated B cells, and performed immunoprecipitations using Abs against Ig␣ or Ig␤, either of which should allow recovery of both Ig␣ and Ig␤ due to the fact that these proteins remain disulfide linked under nonreducing conditions. In both naive and 3-day LPS-stimulated B cells, there was no detectable difference in the association/stoichiometry of Ig␣ and Ig␤ as a result of XBP-1 deficiency (Fig. 3) . The synthesis of Ig␣ and Ig␤ was apparently not affected by the absence of XBP-1 because we detected similar amounts of Ig␣ and Ig␤ in XBP-1 WT and XBP-1 KO B cells (Fig. 3) . Because both Ig␣ and Ig␤ acquire complex-type glycans in the Golgi apparatus, the exit of Ig␣ and Ig␤ from the ER is normal in the absence of XBP-1 (Fig. 3) . Similar results were found in either XBP-1 KO or XBP-1 KO 
/S
Ϫ/Ϫ B cells (Fig. 3) .
Disulfide formation proceeds normally in the absence of XBP-1
XBP-1-deficient B cells did not up-regulate PDI in response to LPS stimulation (Fig. 1A) , consistent with the known mechanism of transcriptional control of the PDI gene by XBP-1 (6, 7). Several components of the BCR associate through disulfide bonds: Ig␣ and Ig␤ form a heterodimer held together by a disulfide bond, as do Ig H () and L () chains to yield IgM. Lysates from XBP-1 WT / S Ϫ/Ϫ and XBP-1 KO /S Ϫ/Ϫ B cells cultured in the presence of LPS for 2 or 4 days were treated with N-ethylmaleimide (NEM) to preserve disulfide bond arrangements and to prevent de novo formation of disulfide bonds. We found no difference in the levels of nonreduced Ig␣/Ig␤ heterodimers in XBP-1 KO /S Ϫ/Ϫ B cells (Fig. 4A) , suggesting that the disulfide bond between them formed normally. Similarly, -and -chains assembled correctly into higher-order dimers ( ϩ ) and tetramers ( 2 2 ) (Fig. 4B) . Thus, the prevailingly low levels of PDI in XBP-1-deficient B cells are sufficient to sustain normal disulfide bond formation.
Normal kinetics of synthesis and ER exit are observed for proteins that enter the secretory pathway in XBP-1-deficient B cells
We investigated protein synthesis and trafficking in XBP-1-deficient B cells by pulse-chase analyses on IgM, -chains, class I MHC, Ig␣/Ig␤, and class II MHC molecules. We detected no defects in the trafficking of mIgM to the cell surface, because levels of the complex oligosaccharide-bearing -chain (indicated by M(ϩ)CHO*) were not altered in XBP-1-deficient B cells after 120 min of chase (Fig. 5) . Although XBP-1-deficient B cells synthesized more -chains (Fig. 1) than their WT counterparts, all of the excess -chains were effectively secreted (Fig. 5B) .
We observed a barely detectable delay in the exit of class I MHC from the ER in XBP-1-deficient B cells as compared with XBP-1-proficient B cells, regardless of whether this was measured for XBP-1 KO /S Ϫ/Ϫ or XBP-1 KO /MD4 mice (Fig. 6, A and B) . At (Fig. 6C) . We also did not detect any difference in the rate of trafficking of class II MHC molecules as a result of XBP-1 deficiency (Fig. 6D) .
XBP-1 deficiency does not alter cell surface display of glycoproteins or compromise their functions
No differences were found in the cell surface levels of CD1d, CD80, or CD40 (Fig. 7, A-C) as measured by cytofluorimetry. Signaling through various TLRs by distinct TLR ligands was indistinguishable for XBP-1 WT /MD4 and XBP-1 KO /MD4 B cells, as measured by the secretion of IL-6 in response to stimulation (Fig.  7D) . Consistently, B cells were found irresponsive to poly(I:C) (26) . The ability of CD1d to present lipid Ags to NKT hybridoma cells was also tested, and no apparent defect was detected in XBP-1-deficient B cells (Fig. 7E) . Thus, all proteins examined function normally in XBP-1-deficient B cells, implying that they do not obviously suffer from a folding or transport defect.
XBP-1-deficient B cells synthesize significantly less PC, SM, and PI
We examined changes in lipid composition of total membranes extracted from both naive and LPS-stimulated XBP-1-deficient B cells using liquid chromatography-mass spectrometry. Data from four independent experiments suggest that the lipid composition in total membranes of the naive XBP-1-deficient B cells is similar to that of the naive XBP-1-proficient B cells. However, significantly lower levels of PC, SM, and PI were found in the membranes of 4-day LPS-stimulated XBP-1-deficient B cells (Fig. 8 and supplemental Fig. S1 ), 4 suggesting that the presence of XBP-1 is required for production of these lipids in LPS-stimulated plasmablasts.
XBP-1-deficient B cells show a reduced expansion of the ER
We investigated expansion of the ER in XBP-1-deficient B cells in response to LPS stimulation. Naive B cells contained relatively little ER, and no differences between the XBP-1-deficient B cells and their WT counterparts were detectable by electron microscopy (Fig. 9) . In both XBP-1-proficient and XBP-1-deficient B cells, 4 The online version of this article contains supplemental material. similar percentages of the cell population respond to LPS stimulation by increasing ER content. The expansion was more pronounced in XBP-1-proficient B cells (Fig. 9) .
XBP-1-deficient B cells have subtly altered patterns of terminal glycosylation
We noticed subtle differences in the patterns of glycosylation of IgM and class I MHC when comparing LPS-stimulated XBP-1-proficient and XBP-1-deficient B cells. XBP-1 WT /MD4 B cells contained more of the ER form of both mIgM and sIgM than XBP-1 KO /MD4 B cells (Fig. 10A) . By carefully investigating the glycosylation status of mIgM, we observed a difference in the mobility of the Endo H-resistant fraction of mIgM between XBP-1 WT /S Ϫ/Ϫ and XBP-1 KO /S Ϫ/Ϫ B cells (Fig. 10B) , and an increased heterogeneity in the acquisition of Endo H-resistant complex-type glycans in XBP-1 KO /S Ϫ/Ϫ B cells (Fig. 10B , indicated by Ͻ). Because each -chain has five potential N-linked glycosylation sites, heterogeneity can arise from any of these sites due to differences in terminal glycosylation. Similar defects in glycosylation also occurred to class I MHC molecules (Fig. 6, A and  B) . The XBP-1-proficient B cells synthesized a population of class I MHC with Endo H-resistant glycan modifications that migrated more slowly in SDS-PAGE, which was absent from XBP-1-deficient B cells (Fig. 6, A and B) . 
Discussion
The UPR is commonly viewed as a stereotypic set of changes in gene expression, triggered by the accumulation of misfolded proteins. Its regulation involves the activation of IRE-1, which executes a splicing reaction to yield XBP-1s mRNA, the translation of which starts a transcriptional program that targets a variety of genes encoding chaperones and enzymes involved in protein folding and lipid synthesis. The literature frequently equates the activation of XBP-1 with the activation of the UPR, a response commonly evoked experimentally through the application of toxic drugs such as tunicamycin, thapsigargin, or DTT. The extent to which the UPR functions in a more physiological manner is not immediately obvious, and none of the above treatments used to induce the UPR can be considered subtle. Tunicamycin treatment interferes with glycoprotein folding through inhibition of glycosylation, but the extent of folding damage inflicted is difficult to gauge. At the same time, tunicamycin treatment also leads to accumulation of the dolichol precursor and presumably affects the lipid environment in which ER membrane proteins function. Thapsigargin depletes the ER of its calcium stores, compromises the function of calcium-dependent ER-resident chaperones such as calnexin and calreticulin, and is therefore expected to increase the failure rate of protein folding in the ER. Imposition of stress by generating a strongly reducing environment using DTT is also a common method to unleash the UPR. All of these triggers activate XBP-1 (3). More rarely the UPR can be induced by overexpression of genetically engineered misfolded proteins (27, 28) , but it is interesting to note that these two examples concern a polytopic (multispanning) ER membrane protein and a surfactant-binding protein, respectively, both of which might act not only through their misfolded state per se, but also through sequestration of lipids and their metabolites at inappropriate locations. Experiments in yeast suggest that massive quantities of a misfolded type I membrane protein are far less effective at induction of the UPR than even mild tunicamycin treatment (29) .
Development of B cells into plasma cells is an example of a physiological process that triggers the UPR, as defined by activation of XBP-1. Although misfolded sIgM has been speculated to provide the impetus for XBP-1 activation in differentiating plasma cells (3, 4) , our data provide no support for this suggestion, because XBP-1 activation occurs also in B cells that cannot make sIgM, with kinetics that mimic those in normal B cells (Fig. 1 ) (10) . Because an excess of unfolded sIgM cannot be the cause of XBP-1 activation in these cells, we conclude that there must be an as yet unidentified (differentiation-dependent) trigger that leads to XBP-1 activation through IRE-1. IRE-1 is usually activated by the presence of unfolded proteins in the lumen of the ER, either through a direct interaction with unfolded proteins (30) , or through its dissociation from Ig H chain binding protein (BiP) as a result of competition for unfolded proteins (31, 32) . Unfolded ER proteins alone may not be sufficient for full IRE-1 activation. Protein-tyrosine phosphatase 1B (PTP-1B) has been implicated in assisting complete function of IRE-1, because cells that lack PTP-1B are less efficient in turning on downstream effectors of IRE-1 in response to UPR triggers (33) , thus linking PTP-1B to IRE-1. Full activation of the IRE-1 pathway can thus be controlled by multiple inputs, and not merely by the presence of unfolded proteins.
LPS-induced differentiation activates XBP-1 (4, 34), leading to up-regulation of chaperones like PDI (Fig. 1A) . Assuming that the failure to increase PDI levels in XBP-1-deficient plasmablasts would cause misassembly and/or misfolding of proteins, we investigated the fate of IgM H and L chains, as well as the ability of IgM to bind HEL in the absence of XBP-1 (Fig. 2) . We saw no difference between XBP-1 WT /MD4 and XBP-1 KO /MD4 plasmablasts in terms of their ability to correctly assemble sIgM and mIgM capable of HEL binding. Free -chains were synthesized at increased levels and were readily secreted by XBP-1-deficient B cells (Figs. 1B and 5 ). XBP-1 deficiency also did not affect synthesis, assembly, and trafficking of Ig␣ and Ig␤, or class I and class II MHC molecules (Figs. 3, 4A , and 6), with the possible exception of a barely perceptible delay in the exit of class I MHC molecules from the ER in XBP-1-deficient B cells (Fig. 6, A and B) . XBP-1-deficient B cells obtained from chimeric XBP-1
mice showed no obvious delay in class I MHC trafficking, a difference we attribute to the slight difference in the pulse-chase protocols used (25) . We hence suggest that glycoproteins fold and function normally in XBP-1-deficient B cells. This conclusion is inconsistent with the proposal that an XBP-1-deficient B cell produces an ER that is defective in protein folding. CD40, CD80, and CD1d were all present at the cell surface of XBP-1-deficient B cells in normal amounts (Fig. 7, A-C) , and CD1d was fully functional in the presentation of lipid Ags to NKT cells (Fig. 7E) . Production of IL-6 triggered by various TLR ligands was not significantly different for XBP-1-proficient and XBP-1-deficient plasmablasts (Fig. 7D) , suggesting that the examined TLRs function properly in their distinct cellular compartments. Taken together, these results show that the ER of XBP-1-deficient plasmablasts sustains folding and assembly of all proteins we have examined to date. The activation of stress responses triggered by prion replication was not influenced by XBP-1 deficiency (11), further supporting the notion that XBP-1 is not required to handle misfolded proteins, in the form of cytotoxic aggregates.
It is possible that we do not detect a defect in protein folding in XBP-1-deficient B cells due to a compensatory up-regulation of other branches of the UPR. In addition to the responses initiated by the IRE-1/XBP-1 axis, RNA-dependent protein kinase (PKR)-like ER kinase (PERK) and activating transcription factor (ATF)6 contribute as well. The presence of unfolded proteins in the ER stimulates phosphorylation by PERK of eukaryotic initiation factor 2␣ (eIF2␣). This attenuates translation initiation, thus reducing the number of proteins that enter the ER (31). However, there is no indication that initiation of translation is somehow compromised through engagement of the PERK axis in XBP-1-deficient B cells. ATF6 is a membrane-bound transcription factor. In response to ER stress, ATF6 traffics to the Golgi apparatus, where its transmembrane segment is cleaved to release its transcription factor domain, which then translocates to the nucleus to initiate the transcription of ER chaperones that can aid in protein folding (35, 36) . The PERK branch of the UPR is not required for B cell differentiation (37) , and XBP-1 deficiency does not lead to the up-regulation of eIF2␣ and phospho-eIF2␣, important indictors for PERK activation (10) (data not shown). The ATF6 pathway is induced during plasma cell differentiation (38) , but whether it is essential for plasma cell differentiation remains to be established. Finally, XBP-1 deficiency alone is sufficient to cause a block in plasma cell differentiation, with no obvious compensation by either PERK or ATF6 activation.
The exact role of XBP-1 in plasma cell differentiation remains to be defined. PC, SM, and PI decrease in response to XBP-1 deficiency in total membranes of LPS-stimulated plasmablasts cells, but not unstimulated naive B cells (Fig. 8 and supplemental  Fig. S1 ), suggesting that XBP-1 is required for lipid synthesis in support of plasma cell differentiation. PC is most drastically affected by XBP-1 deficiency in plasmablasts because it is the primary phospholipid of the ER membranes. Although no lipid was found altered in hepatocytes lacking XBP-1 (17), PC and phosphatidylethanolamine increase significantly in NIH3T3 fibroblasts overexpressing XBP-1s (15, 16) . Unlike in fibroblasts, we do not find phosphatidylethanolamine affected by XBP-1 deficiency in B cells; however, SM and PI decrease significantly in XBP-1-deficient plasmablasts, although the levels of these two lipids are lower than that of PC. To find reduced levels of SM and PI in plasmablasts is interesting, because both lipids play important roles in signal transduction. SM is a crucial lipid in rafts, and PI is an essential intermediate in the PI-3-phosphate signaling pathway. These lipid defects may compromise the recruitment of IgM, Ig␣/Ig␤, and other B cell coreceptors (CD19, CD20, CD21, and CD81) into lipid rafts, and contribute to the observed defective signal transduction in XBP-deficient B cells (10) .
Activated XBP-1-deficient plasmablasts had decreased ER content compared with XBP-1-proficient plasmablasts, as visualized by transmission electron microscopy ( Fig. 9) , whereas unstimulated controls showed no such difference. Although XBP-1 is not required for B cells to increase their ER content in response to differentiation, the extent of the ER expansion does depend on XBP-1. This is consistent with XBP-1's role in setting the levels of PC ( Fig. 8 and supplemental Fig. S1A ). Thus, it appears that expansion of the ER, but not necessarily the ER-folding capacity per se, is under the control of XBP-1.
We observed minor differences in the pattern of terminal glycosylation of both IgM and class I MHC in XBP-1-deficient cells (Figs. 6, A and B, and 10 ). Although these changes are slight and require a more detailed analysis by glycan sequencing, such differences could certainly contribute to the defect in plasma cell differentiation in XBP-1-deficient mice. Whether alterations in glycosyltransferase levels, nucleotide sugars, and their transporters or the environment in which these enzymes function are responsible for the observed glycosylation defects is not known at present. Proper glycosylation is most likely critical to B cell differentiation, given that the blockade of high mannose to complextype N-linked glycans imposed by the ER mannosidase inhibitor 1-deoxymannojirimycin can completely block the formation of Igsecreting B cell blasts from human peripheral blood B cells (39) , although mannosidase inhibition does not inhibit B cell proliferation or Ig secretion per se. Some factors required for B cell differentiation may well be sensitive to changes in terminal glycan modifications.
XBP-1 WT /MD4 and XBP-1 KO /MD4 B cells differ in signaling through the BCR, and regulation of the transcription factors IFN regulatory factor 4 and Blimp-1 (10) . In addition, XBP-1-deficient B cells after Ag stimulation fail to migrate to the bone marrow (10) . These, together with altered lipid synthesis and glycosylation in XBP-1-deficient B cells, could account for failure of B cells to fully differentiate into plasma cells, but accumulation of misfolded proteins does not appear to be a key contributing factor. Altogether, our results suggest that XBP-1 activation in B cells is a differentiation-dependent event unlinked to accumulation of misfolded IgM. Furthermore, protein folding occurs normally in XBP-1-deficient B cells, indicating an essential role for XBP-1 beyond the UPR.
